Get the Stockscreener App
17.85
0.03%
-0.005
After Hours:
17.60
-0.25
-1.40%
Quince Therapeutics Inc stock is traded at $17.85, with a volume of 18,032.
It is down -0.03% in the last 24 hours and down -5.41% over the past month.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
See More
Previous Close:
$17.86
Open:
$17.72
24h Volume:
18,032
Relative Volume:
0.32
Market Cap:
$17.46M
Revenue:
-
Net Income/Loss:
$-33.04M
P/E Ratio:
-1.961
EPS:
-9.1023
Net Cash Flow:
$-39.66M
1W Performance:
-5.15%
1M Performance:
-5.41%
6M Performance:
-97.30%
1Y Performance:
-95.18%
1-Day Range:
$17.60
$18.49
1-Week Range:
$17.50
$19.14
52-Week Range:
$15.10
$909.98
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
17.85 | 17.46M | 0 | -33.04M | -39.66M | -9.1023 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quince Therapeutics Inc (QNCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
Quince Therapeutics Inc (QNCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quince Therapeutics Inc (QNCX) Institutional Confidence - TradingKey
Quince Therapeutics Inc (QNCX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quince Therapeutics Inc (QNCX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quince Therapeutics Inc (QNCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quince Therapeutics, Inc. Revenue Breakdown – NASDAQ:QNCX - TradingView
QNCX|Quince Therapeutics Inc|Price:17.740|Chg%:-0.540 - TradingKey
QUINCE THERAPEUTICS INC (QNCX) Stock Chart - ChartMill
Quince Therapeutics Inc. Q1 2026 Earnings: Massive EPS Surprise Driven by One-Time GainEarnings Forecast Report - dars.gov.et
Quince Therapeutics Surges Over 11% as Biotech Momentum BuildsAdvance Decline Line - dars.gov.et
Quince Therapeutics updates its strategy as a clinical-stage biotech. QNCX focuses on targeted drug - Ad Hoc News
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - The National Law Review
QNCX Should I Buy - Intellectia AI
What date does Quince Therapeutics, Inc.'s (QNCX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
$Quince Therapeutics (QNCX.US)$ fake news !!! - Moomoo
HCW Biologics Inc.: Top Mutual Funds Holders | QNCX | US40423R3030 - marketscreener.com
QNCX Q1 2026 Earnings: Massive EPS Surprise Amid Stock Decline Raises QuestionsDiluted EPS Report - dars.gov.et
Quince Therapeutics forms advisory board for LAM-001 drug - Investing.com
Quince Therapeutics forms advisory board for LAM-001 drug By Investing.com - Investing.com India
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board - GlobeNewswire
LifeSci Capital Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $100 - Moomoo
Quince Therapeutics Implements 1-for-20 Reverse Stock Split - The Globe and Mail
Quince Therapeutics, Inc. Files 8-K/A Amendment to Correct Reverse Stock Split Description – Key SEC Filing Details - Minichart
Quince Therapeutics Inc. (QNCX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Quince Therapeutics (QNCX) confirms 1-for-20 reverse split and sharp share reduction - Stock Titan
1-for-20 reverse split consolidates Quince Therapeutics (NASDAQ: QNCX) shares - Stock Titan
Price to sales forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Enterprise value to revenue forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Price to book forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Price to earnings forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Enterprise value to EBIT forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Quince Therapeutics, Inc. Actuals & Estimates (NASDAQ:QNCX) - TradingView
Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating By Investing.com - Investing.com South Africa
QNCX Forecast — Price Target — Prediction for 2027 - TradingView
Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight - Investing.com
Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating - Investing.com
Cantor Fitzgerald Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
$Quince Therapeutics (QNCX.US)$ - Moomoo
QNCX Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Leerink Partners Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Leerink initiates Quince Therapeutics stock with Outperform rating By Investing.com - Investing.com Australia
Leerink Partners Initiates Quince Therapeutics at Outperform With $4 Price Target - marketscreener.com
Leerink initiates Quince Therapeutics stock with Outperform rating - Investing.com
QNCX Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus
Cantor Fitzgerald initiates Quince Therapeutics stock with overweight rating - Investing.com UK
Cantor Fitzgerald initiates Quince Therapeutics stock with overweight rating By Investing.com - Investing.com South Africa
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):